Leukemia Research
Volume 33, Issue 11 , Pages 1570-1573 , November 2009

Comparative analysis of IL6 promoter and receptor polymorphisms in myelodysplasia and multiple myeloma

  • I. Aladzsity

      Affiliations

    • 3rd Department of Internal Medicine, Semmelweis University, 1125 Budapest, Hungary
    • ,
  • M. Kovács

      Affiliations

    • 3rd Department of Internal Medicine, Semmelweis University, 1125 Budapest, Hungary
    • ,
  • Á. Semsei

      Affiliations

    • Department of Genetics, Cell and Immunobiology, Semmelweis University, Budapest, Hungary
    • ,
  • A. Falus

      Affiliations

    • Department of Genetics, Cell and Immunobiology, Semmelweis University, Budapest, Hungary
    • ,
  • Á. Szilágyi

      Affiliations

    • 3rd Department of Internal Medicine, Semmelweis University, 1125 Budapest, Hungary
    • ,
  • I. Karádi

      Affiliations

    • 3rd Department of Internal Medicine, Semmelweis University, 1125 Budapest, Hungary
    • ,
  • G. Varga

      Affiliations

    • 3rd Department of Internal Medicine, Semmelweis University, 1125 Budapest, Hungary
    • ,
  • G. Füst

      Affiliations

    • 3rd Department of Internal Medicine, Semmelweis University, 1125 Budapest, Hungary
    • Corresponding Author InformationCorresponding author.
    • ,
  • J. Várkonyi

      Affiliations

    • 3rd Department of Internal Medicine, Semmelweis University, 1125 Budapest, Hungary

Received 28 November 2008 ,Revised 13 February 2009 ,Accepted 9 March 2009.

References 

  1. Sfiridaki A, Miyakis S, Tsirakis G, Alegakis A, Passam AM, Kandidaki E, et al. Systemic levels of interleukin-6 and matrix metalloproteinase-9 in patients with multiple myeloma may be useful as prognostic indexes of bone disease. Clin Chem Lab Med. 2005;43:934–938
  2. Kuku I, Bayraktar MR, Kaya E, Erkurt MA, Bayraktar N, Cikim K, et al. Serum proinflammatory mediators at different periods of therapy in patients with multiple myeloma. Mediators Inflamm. 2005;2005:171–174
  3. Alexandrakis MG, Passam FH, Ganotakis ES, Sfiridaki K, Xilouri I, Perisinakis K, et al. The clinical and prognostic significance of erythrocyte sedimentation rate (ESR), serum interleukin-6 (IL-6) and acute phase protein levels in multiple myeloma. Clin Lab Haematol. 2003;25:41–46
  4. Sefer D, Marisavjlevic D, Bogdanovic A, Andrejevic S, Boskovic D, Suvajdiid N, et al. Circulating interleukin-6 (IL-6) in patients with myelodysplastic syndromes. Leukemia Res. 1999;23:S23–S28[Abstr 78]
  5. Meyers CA, Albitar M, Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer. 2005;104:788–793
  6. Ershler WB, Keller ET. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu Rev Med. 2000;51:245–270
  7. Cozen W, Gebregziabher M, Conti DV, Van Den Berg DJ, Coetzee GA, Wang SS, et al. Interleukin-6-related genotypes, body mass index, and risk of multiple myeloma and plasmacytoma. Cancer Epidemiol Biomarkers Prev. 2006;15:2285–2291
  8. Dring AM, Davies FE, Rollinson SJ, Roddam PL, Rawstron AC, Child JA, et al. Interleukin 6, tumour necrosis factor alpha and lymphotoxin alpha polymorphisms in monoclonal gammopathy of uncertain significance and multiple myeloma. Br J Haematol. 2001;112:249–251
  9. Mazur G, Bogunia-Kubik K, Wrobel T, Karabon L, Polak M, Kuliczkowski K, et al. IL-6 and IL-10 promoter gene polymorphisms do not associate with the susceptibility for multiple myeloma. Immunol Lett. 2005;96:241–246
  10. Zheng C, Huang DR, Bergenbrant S, Sundblad A, Osterborg A, Bjorkholm M, et al. Interleukin 6, tumour necrosis factor alpha, interleukin 1beta and interleukin 1 receptor antagonist promoter or coding gene polymorphisms in multiple myeloma. Br J Haematol. 2000;109:39–45
  11. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215
  12. Duch CR, Figueiredo MS, Ribas C, Almeida MS, Colleoni GW, Bordin JO. Analysis of polymorphism at site −174 G/C of interleukin-6 promoter region in multiple myeloma. Braz J Med Biol Res. 2007;40:265–267
  13. Rose-John S, Scheller J, Elson G, Jones SA. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol. 2006;80:227–236
  14. Galicia JC, Tai H, Komatsu Y, Shimada Y, Akazawa K, Yoshie H. Polymorphisms in the IL-6 receptor (IL-6R) gene: strong evidence that serum levels of soluble IL-6R are genetically influenced. Genes Immun. 2004;5:513–516
  15. Rafiq S, Frayling TM, Murray A, Hurst A, Stevens K, Weedon MN, et al. A common variant of the interleukin 6 receptor (IL-6r) gene increases IL-6r and IL-6 levels, without other inflammatory effects. Genes Immun. 2007;8:552–559
  16. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest. 1998;102:1369–1376
  17. Olivieri F, Bonafe M, Cavallone L, Giovagnetti S, Marchegiani F, Cardelli M, et al. The −174C/G locus affects in vitro/in vivo IL-6 production during aging. Exp Gerontol. 2002;37:309–314
  18. Muller-Steinhardt M, Ebel B, Hartel C. The impact of interleukin-6 promoter −597/−572/−174genotype on interleukin-6 production after lipopolysaccharide stimulation. Clin Exp Immunol. 2007;147:339–345
  19. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood. 2003;101:2461–2463
  20. Varkonyi J, Demeter J, Tordai A, Andrikovics H. The significance of the hemochromatosis genetic variants in multiple myeloma in comparison to that of myelodysplastic syndrome. Ann Hematol. 2006;85:869–871
  21. Pietrangelo A, Trautwein C. Mechanisms of disease: the role of hepcidin in iron homeostasis—implications for hemochromatosis and other disorders. Nat Clin Pract Gastroenterol Hepatol. 2004;1:39–45
  22. Pietrangelo A, Dierssen U, Valli L, Garuti C, Rump A, Corradini E, et al. STAT3 is required for IL-6-gp130-dependent activation of hepcidin in vivo. Gastroenterology. 2007;132:294–300
  23. Varkonyi J, Tarkovacs G, Karadi I, Andrikovics H, Varga F, Varga F, et al. High incidence of hemochromatosis gene mutations in the myelodysplastic syndrome: the Budapest Study on 50 patients. Acta Haematol. 2003;109:64–67
  24. Nearman ZP, Szpurka H, Serio B, Warshawksy I, Theil K, Lichtin A, et al. Hemochromatosis-associated gene mutations in patients with myelodysplastic syndromes with refractory anemia with ringed sideroblasts. Am J Hematol. 2007;82:1076–1079

PII: S0145-2126(09)00117-9

doi: 10.1016/j.leukres.2009.03.009

Leukemia Research
Volume 33, Issue 11 , Pages 1570-1573 , November 2009

Article Tools